India-EU free trade agreement threatens access to generic drugs, MSF warnsBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c2309 (Published 27 April 2010) Cite this as: BMJ 2010;340:c2309
- Peter Moszynski
A free trade agreement being negotiated between India and the European Union could radically restrict access to cheap generic drugs across the developing world, says the charity Médecins Sans Frontières.
The charity held a press conference in Brussels this week to warn of the dangers presented to the supply of generic drugs by provisions on intellectual property rights being discussed at a closed meeting at the European Union.
MSF points out that India is the source of 80% of the antiretrovirals it uses in its projects and maintains that “without quality affordable medicines from Indian sources, it would have been impossible to scale up treatment to the levels seen today, and millions of lives would not have been saved.”
It says …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial